Table 2.
Detailed information about medications used in the study cohort
| Patients | Prednisolone (mg/day) | MTX (mg/week) | Other |
|---|---|---|---|
| Pre-RTX | |||
| 1 | 0 | 12.5 | |
| 2 | 5 | 25 | |
| 3 | 7.5 | 20 | |
| 4 | 6.25 | 10 | |
| 5 | 10 | 20 | |
| Post-RTX | |||
| 1 | 5 | 20 | |
| 2 | 0 | 20 | Cyclosporin A |
| 3 | 0 | 25 | |
| 4 | 0 | 15 | |
| 5 | 5 | 10 | |
| 6 | 5 | 25 | |
| 7 | 0 | 2.5 | Azathioprine |
| 8 | 0 | 10 | |
| 9 | 2.5 | 22.5 | Cyclosporin A |
| 10 | 0 | 20 | |
| 11 | 5 | 10 | |
| Controls | |||
| 1 | 0 | 15 | Sulfasalazine |
| 2 | 5 | 10 | |
| 3 | 0 | 25 | Sulfasalazine |
| 4 | 0 | 10 | Hydroxychlorokin + cyclosporin A |
| 5 | 0 | 20 | Hydroxychlorokin |
| 6 | 0 | 20 | Etanercept |
| 7 | 0 | 20 | |
| 8 | 0 | 25 | Hydroxychlorokin |
| 9 | 0 | 20 | Infliximab |
| 10 | 0 | 20 | |
MTX, methotrexate; RTX, rituximab.